Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628197 | 0.95 | NPC1 (0.39) | NPC1RAB9APOLBNPSR1CXCR5 | |
| SCHEMBL13628199 | 0.92 | MAPT (0.40) | NPC1RAB9APOLBNPSR1MAPK14 | |
| SCHEMBL13628274 | 0.92 | KMT2A (0.37) | RPS6KA2NPC1RAB9APOLBNPSR1 | |
| SCHEMBL13628202 | 0.92 | NPC1 (0.42) | NPC1RAB9APOLBNPSR1ROCK2 | |
| SCHEMBL13637453 | 0.91 | RPS6KA2 (0.42) | RPS6KA2NPC1RAB9ANPSR1MAPK14 | |
| SCHEMBL13628302 | 0.91 | RAB9A (0.42) | NPC1RAB9APOLBNPSR1CXCR5 | |
| SCHEMBL13628196 | 0.90 | NPC1 (0.43) | RPS6KA2NPC1RAB9APOLBMAPK14 | |
| SCHEMBL13628207 | 0.90 | MEN1 (0.41) | NPC1RAB9APOLB | |
| SCHEMBL13628200 | 0.90 | NPC1 (0.45) | NPC1RAB9APOLBNPSR1MAPK8 | |
| SCHEMBL13628170 | 0.90 | MAPT (0.45) | NPC1RAB9APOLBNPSR1CXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | MAP3K1, JUN, MAP3K7 | RPS6KA2 374/4885NPC1 1715/4885RAB9A 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.